Trial · NCT00375713
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score). | Levocetirizine | Responder | 131 | Participants | |
| Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score). | Cetirizine | Responder | 134 | Participants | |
| Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score). | Levocetirizine | Non-Responder | 37 | Participants | |
| Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score). | Cetirizine | Non-Responder | 38 | Participants | |
| Change From Baseline in the Mean Pruritus Severity Score at Endpoint During the 14 Day Treatment Period | Levocetirizine | 1.15 | Standard Error 0.05 | Units on a scale | |
| Change From Baseline in the Mean Pruritus Severity Score at Endpoint During the 14 Day Treatment Period | Cetirizine | 1.21 | Standard Error 0.05 | Units on a scale | |
| Duration of Pruritus (Stated in Categories) at Endpoint During the 14 Day Treatment Period | Levocetirizine | 2.13 | Standard Error 0.05 | Units on a scale | |
| Duration of Pruritus (Stated in Categories) at Endpoint During the 14 Day Treatment Period | Cetirizine | 2.20 | Standard Error 0.05 | Units on a scale | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Levocetirizine | Marked improvement | 47 | Participants | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Cetirizine | Marked improvement | 52 | Participants | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Levocetirizine | Moderate improvement | 62 | Participants | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Cetirizine | Moderate improvement | 54 | Participants | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Levocetirizine | Mild improvement | 39 | Participants | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Cetirizine | Mild improvement | 47 | Participants | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Levocetirizine | No change | 18 | Participants | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Cetirizine | No change | 15 | Participants | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Levocetirizine | Exacerbation | 1 | Participants | |
| Global Improvement at Endpoint During the 14 Day Treatment Period | Cetirizine | Exacerbation | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00375713/results